Registration

May 10, 2022

PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).

Early FAPI-PET scans match 60-minute scans for lung cancer staging

June 10, 2026

AI for CT & PET/CT Imaging

AI for CT & PET/CT Imaging

June 4, 2026

Experts gathered at the European Conference on Interventional Oncology ECIO 2026 in Basel to discuss the latest advances in minimally invasive cancer care.

ECIO 2026: interventional oncology's next step

June 9, 2026

Breast Cancer Social

What's the optimum approach for B3 breast lesions?

June 9, 2026

Early FAPI-PET scans match 60-minute scans for lung cancer staging

By convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.

June 10, 2026

PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).

AI gives a boost to cardiac MRI risk prediction

By Kate Madden Yee

Accurate risk prediction for coronary heart disease helps clinicians guide patient therapy and follow-up.

June 10, 2026

C-index for Cox regression and random survival forests models using two feature sets. Adding historical registry data decreases the C-index for Cox regression but increased it for the random survival forests model, consistent with the non-linear structure in the registry data.

ECIO 2026: interventional oncology's next step

By Claudia Tschabuschnig

At ECIO 2026 in Basel, experts highlighted how multidisciplinary collaboration, patient selection, and evidence generation are shaping the next phase of the specialty.

June 9, 2026

Experts gathered at the European Conference on Interventional Oncology ECIO 2026 in Basel to discuss the latest advances in minimally invasive cancer care.

What's the optimum approach for B3 breast lesions?

Certain B3 lesion types should be screened more often, researchers from a top London hospital have asserted at the U.K. Imaging and Oncology Congress (UKIO).

June 9, 2026

Breast Cancer Social

AI may provide early breast cancer alerts from mammograms

By Amerigo Allegretto

Commercial AI systems could provide early alerts for breast cancer by picking out early signs of the disease on mammograms.

June 9, 2026

Screening mammograms and AI score changes are depicted over time in two individuals with screen-detected cancer. Full-field digital mammograms show craniocaudal (top) and mediolateral (bottom) views of the left and right breast. The description below each mammogram indicates whether AI scores from three AI-based computer-aided detection systems (AI-1, AI-2, and AI-3) were above or below the 90th percentile. (A) Mammograms from three screening time points (in 2009, 2011, and 2014) in an individual who was diagnosed in February 2014 (at age 73 years) with a left-sided 25-mm grade 2 invasive breast carcinoma, no special type (arrow). Mammographic breast density was classified as BI-RADS B on all three mammograms. (B) Mammograms from four screening time points (in 2009, 2011, 2013, and 2015) in an individual who was diagnosed in October 2015 (at age 65 years) with a left-sided 45-mm grade 2 lobular carcinoma (arrow). Mammographic breast density was classified as BI-RADS C on all four mammograms. Screen-detected cancers were defined as those diagnosed within 90 days for individuals who were recalled at screening (*).

Tattoo pigments can have significant impact on imaging

Tattoos can appear as shadows or artifacts on an x-ray, causing confusion during interpretation. Research presented at the U.K. Imaging and Oncology congress has provided new data on which tattoo inks have the greatest impact.

June 8, 2026

2026 06 08 Tattoos Homepage Image

SERAM 2026: Biparametric MRI cuts time and costs in prostate cancer imaging

By Claudia Tschabuschnig

A study presented at SERAM 2026 suggests that biparametric MRI (bpMRI) can reduce exam time and costs in patients with clinically significant prostate cancer.

June 8, 2026

Biparametric prostate MRI identified clinically significant Gleason 3+4 prostate cancer using T2-weighted imaging, diffusion-weighted imaging, and ADC mapping alone.

SCCT, SCAI publish fractional flow reserve in CCTA guideline

By AuntMinnie.com staff writers

The document was crafted by a team from King's College London in the U.K.

June 8, 2026

SERAM 2026: AI chest triage cuts referrals without raising CT use

By Claudia Tschabuschnig

A real-world implementation study from a Spanish regional hospital suggests that AI-assisted chest radiograph triage may reduce specialist referrals without driving additional CT imaging.

June 4, 2026

An AI system highlights multiple abnormalities on a chest radiograph, including a pulmonary nodule (nódulo pulmonar), pleural effusion (derrame pleural), and alveolar syndrome/consolidation (síndrome alveolar).

AI detects lung cancer nodules well but shows low specificity

By Kate Madden Yee

The finding suggests the models offer “a potential role as adjunctive tools for ruling out malignancy” rather than classifying it.

June 4, 2026

Am 2020 06 26 16 29 2945 Cancer Lung 400

Royal Philips, WellSpan Health announce seven-year imaging alliance

By AuntMinnie.com staff writers

Royal Philips and WellSpan Health have entered a strategic alliance to bring new imaging products to WellSpan's health system.

June 4, 2026

WellSpan New York Hospital

Image-guided focal laser ablation effective for prostate cancer

By Amerigo Allegretto

MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Page 1 of 1323